Suzuki Atsushi
   Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine
   Position   Assistant Professor
Article types Original article
Language English
Peer review Peer reviewed
Title Effectiveness and safety of dabigatran versus warfarin in real-world Japanese patients with atrial fibrillation: A single-center observational study
Journal Formal name:Journal of Arrhythmia
Abbreviation:J Arrhythmia
ISSN code:1880-4276/1883-2148
Domestic / ForeginDomestic
Publisher Japanese Heart Rhythm Society
Volume, Issue, Page 33(2),107-110頁
Author and coauthor NAGANUMA Miyoko†, SHIGA Tsuyoshi*, NAGAO Takehiko, SUZUKI Atsushi, MURASAKI Kagari, HAGIWARA Nobuhisa
Publication date 2017/04
In "real-world" practice, anticoagulant therapy is indicated for patients whose clinical profiles are not addressed in randomized clinical trials. We assessed the effectiveness and safety of dabigatran versus warfarin in "real-world" Japanese patients with non-valvular atrial fibrillation (NVAF).

Among 613 NVAF patients who initiated dabigatran or warfarin therapy during the period between 2011 and 2013, 362 patients were included in the study after propensity score adjustment. The median follow-up period was 1.3 years. The effectiveness and safety outcomes were thromboembolism and major bleeding, respectively.

The propensity-matched hazard ratios of thromboembolism and major bleeding with dabigatran were 1.03 (95% CI: 0.12-8.04, p=0.971) and 0.15 (95% CI: 0.01-0.90, p=0.037), respectively.

The ability of dabigatran to prevent thromboembolism is comparable to that of warfarin; however, the major bleeding rate is lower with dabigatran in "real-world" NVAF patients.
PMID 28416975